Interventional Studies

Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: University of Virginia

IPF Drug Deposition Study (Topical-IPF)
Sponsor: Royal Brompton & Harefield NHS Foundation Trust

A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis
Sponsor: AstraZeneca

A Study of the Pharmacokinetics and Deposition of Inhaled Salbutamol in Patients With Idiopathic Pulmonary Fibrosis (TOPICAL-IPF)
Sponsors:
Royal Brompton & Harefield NHS Foundation Trust
GlaxoSmithKline

A Study to Characterize Lung Function, Airway Morphometry, Pharyngometry and Inhalation Profiles From Patients With Idiopathic Pulmonary Fibrosis (IPF)
Sponsors:
GlaxoSmithKline
The University Hospital Antwerp and the University Antwerp

Pilot Study Phase III to Evaluate the Efficacy and Safety of Trimethoprim-sulfamethoxazole in the Treatment of Idiopathic Pulmonary Fibrosis
Sponsors:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Junta de Andalucia

Clinical Utility of Fibered Confocal Fluorescence Microscopy Imaging in Patients With Diffuse Parenchymal Lung Diseases
Sponsor: Singapore General Hospital

Prospective, Longitudinal Cohort Trial of Patients With Idiopathic Pulmonary Fibrosis (IPF) and Healthy Control Patients. Clinical Data, Blood, and Bronchiolavage (BAL) Fluid Will be Collected Over 12 Months.
Sponsor: University of California, San Francisco

Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)
Sponsor/Collaborators: 
Newcastle-upon-Tyne Hospitals NHS Trust
Newcastle University

Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients
Sponsor/Collaborators: 
GlaxoSmithKline
The University Hospital Antwerp and the University Antwerp

A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: Gilead Sciences

A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: GlaxoSmithKline

Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis
Sponsor: Kasiak Research Pvt. Ltd.

Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole
Sponsor/Collaborators:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Junta de Andalucia

Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis
Sponsor: Clinica Universidad de Navarra, Universidad de Navarra

Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
Sponsor: FibroGen

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: Boehringer Ingelheim

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
Sponsor: Bristol-Myers Squibb

A Validation and Dosimetry Study of GSK2634673F PET Ligand
Sponsor: GlaxoSmithKline

Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)
Sponsor/Collaborators: 
University of Miami
Joshua M Hare
Lester and Sue Smith Foundation
The EMMES Corporation

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Sponsor: MedImmune LLC

A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Sponsor: Hoffmann-La Roche

Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis
Sponsor/Collaborators: 
University of Pittsburgh 
National Institutes of Health (NIH)

D2212C00002 J-Phase II Study
Sponsor/Collaborators: 
AstraZeneca 
MedImmune LLC

Nandrolone Decanoate in the Treatment of Telomeropathies
Sponsor/Collaborators: 
University of Sao Paulo
Conselho Nacional de Desenvolvimento Científico e Tecnológico

The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease
Sponsor/Collaborators: 
National Institutes of Health Clinical Center (CC) 
George Mason University

Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
Sponsor/Collaborators: 
Assistance Publique - Hôpitaux de Paris 
Service de Médecine Interne de l'hôpital Claude-Huriez, Lille, France - Pr David Launay

Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
Sponsor: InterMune